Heron Therapeutics, Inc.
Here’s whether Heron Therapeutics, Inc. (HRTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-9.07% over 10 days); RSI 77 — overbought, elevated pullback risk; weak 1-year return of -45.6%; 3-month momentum negative (-32.9%). Currently 61.7% off its 52-week high. Score: -5/7.
HRTX is trading below its 200-day MA ($1.30) — a key warning sign the longer-term trend is under pressure. With an RSI of 77.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -45.6% compares to +35.1% for SPY (trailed the market by 80.7%). The current 61.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.